Role of phosphate retention in the progression of renal failure
- PMID: 8320487
Role of phosphate retention in the progression of renal failure
Abstract
Dietary phosphorus restriction can prevent the progression of renal failure in subtotally nephrectomized rats or in rats with nephrotoxic serum nephritis, independent of protein and caloric intake. Conversely, diets high in phosphorus content result in a more rapid deterioration of renal function. The results are less compelling in indicating that phosphorus restriction can slow the progression of renal failure in the clinical setting. The toxicity of phosphate appears to be related to induction of calcium phosphate precipitation, resulting in tubulointerstitial disease. Most studies of prevention of renal calcification have addressed a single pathway in the development of nephrocalcinosis. These include inhibitors of calcium phosphate precipitation, calcium channel blockers, or an inhibitor of PTH secretion. All of these studies have shown a beneficial effect in preserving renal function. It is possible that a combination of these agents, started early in the course of CRF, may have an additive effect in preventing the progression to ESRD. The discussion of other factors associated with progression of renal failure is beyond the scope of this review. It is obvious that dietary protein restriction, treatment of systemic and intraglomerular hypertension and lipid abnormalities, and prevention of iron overload, all play roles in the preservation of renal function in CRF.
Similar articles
-
[Effect of PTH, phosphate, and metabolic acidosis on the progression of renal insufficiency in the azotemic rat].Nefrologia. 2003;23 Suppl 2:37-42. Nefrologia. 2003. PMID: 12778852 Spanish.
-
Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency.Nephrol Dial Transplant. 2003 Oct;18(10):2014-23. doi: 10.1093/ndt/gfg309. Nephrol Dial Transplant. 2003. PMID: 13679475
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Effect of ammonium chloride and dietary phosphorus in the azotaemic rat. Part II--Kidney hypertrophy and calcium deposition.Nephrol Dial Transplant. 2004 Aug;19(8):1993-8. doi: 10.1093/ndt/gfh301. Epub 2004 May 25. Nephrol Dial Transplant. 2004. PMID: 15161952
-
[Control of calcium and phosphate metabolism and prevention of vascular calcifications in uremic patients].G Ital Nefrol. 2005 Jan-Feb;22 Suppl 31:S47-52. G Ital Nefrol. 2005. PMID: 15786402 Review. Italian.
Cited by
-
Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity.Drug Saf. 1997 Mar;16(3):205-31. doi: 10.2165/00002018-199716030-00005. Drug Saf. 1997. PMID: 9098657 Review.
-
Safety of new phosphate binders for chronic renal failure.Drug Saf. 2003;26(15):1093-115. doi: 10.2165/00002018-200326150-00003. Drug Saf. 2003. PMID: 14640773 Review.
-
Phosphate overload accelerates vascular aging in uremic patients.Heart Int. 2006;2(1):6. doi: 10.4081/hi.2006.6. Epub 2006 May 28. Heart Int. 2006. PMID: 21977245 Free PMC article.
-
Emerging risk factors and markers of chronic kidney disease progression.Nat Rev Nephrol. 2009 Dec;5(12):677-89. doi: 10.1038/nrneph.2009.173. Nat Rev Nephrol. 2009. PMID: 19935815 Review.
-
Phosphate-Induced Renal Fibrosis Requires the Prolyl Isomerase Pin1.PLoS One. 2016 Feb 25;11(2):e0150093. doi: 10.1371/journal.pone.0150093. eCollection 2016. PLoS One. 2016. PMID: 26914452 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical